Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard
| Autor: | V Vlasáková, B. Gömör, Urbanová Z, J Vítová, I Rybár, B Rojkovich, L Green, S Mackiewicz, K Toth, B Siro, Shaul Sukenik, Karel Pavelka, K Bernacka, A Filipowicz-Sosnowska, H Maldyk, Michael Ehrenfeld, R. Becvar, J Bereczki |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
medicine.medical_specialty Diclofenac Adolescent Gastrointestinal Diseases Nabumetone Population Osteoarthritis Gastroenterology Osteoarthritis Hip law.invention Rheumatology Randomized controlled trial law Internal medicine medicine Humans Endoscopy Digestive System Intestinal Mucosa education Aged Pain Measurement Aged 80 and over Gastrointestinal tract education.field_of_study business.industry Stomach Anti-Inflammatory Agents Non-Steroidal General Medicine Middle Aged Osteoarthritis Knee medicine.disease Butanones Surgery stomatognathic diseases medicine.anatomical_structure Treatment Outcome Gastric Mucosa Duodenum Safety business medicine.drug |
| Zdroj: | Clinical rheumatology. 18(4) |
| ISSN: | 0770-3198 |
| Popis: | The aim of the study was to compare the efficacy and the effects on the mucosa of the gastrointestinal tract (GIT) of nabumetone and diclofenac retard in patients with osteoarthritis (OA). An open, multicentre, randomised, comparative, endoscopy-blind parallel group study included 201 patients with nabumetone and 193 patients with diclofenac retard suffering from moderate to severe OA of the knee or hip joint. Twelve clinical efficacy variables were assessed and a portion of the population underwent gastroduodenoscopy. All patients exhibited significant improvement in pain severity and pain relief (p50.001 and p50.0001, respectively) but there were no differences between the groups for all the efficacy variables. Eleven per cent of patients on nabumetone and 19% on diclofenac experienced GIT side-effects. Sixty-nine patients with nabumetone and 61 with diclofenac underwent gastroduodenoscopy. The differences in the mucosal grade for the oesophagus, stomach and duodenum at baseline were not significant. In the oesophagus there were significantly less changes after treatment with nabumetone (p = 0.007) than with diclofenac; there were similar findings in the stomach (p50.001) but the difference in the duodenum was not significant. This study indicates that nabumetone and diclofenac retard have similar efficacy in the treatment of OA, but nabumetone has significantly fewer GIT side-effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink